1. Volume 134, Issue 5, Pages 1385-1395.e1 (May 2008)
Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41 
Christoph S. Klade, Heiner Wedemeyer, Thomas Berg, Holger Hinrichsen, Grazyna Cholewinska, Stefan Zeuzem, Hubert Blum, Michael Buschle, Sandra Jelovcan, Vera Buerger, Erich Tauber, Juergen Frisch, Michael P. Manns 
Gastroenterology 
Volume 134, Issue 5, Pages e1 (May 2008)
DOI: /j.gastro
Copyright © 2008 AGA Institute Terms and Conditions

2. Figure 1
Primary end point immunogenicity: CD4+ T-cell proliferation. (A) Responder rates per dose group. Up to 67% of patients responded to the optimal IC41 dose, whereas only 17% responded to the peptide only vaccinations. (B) Median of HCV specific CD4+ T-cell proliferation (sum stimulation index [SI] of the 3 class II peptides in IC41) per dose group (ITT population) over time.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

3. Figure 2
IC41 but not peptide (or adjuvant) alone induces IFN-γ secreting T cells in chronic HCV patients: up to one third of patients (4 out of 12) treated with the optimal dose of IC41 developed significant IFN-γ responses to the 3 class II CD4 + T-cell epitopes contained in the vaccine. One quarter of patients (3 out of 12) showed CD4+ T helper responses and responses to the 4 class I CD8 + T-cell epitopes.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

4. Figure 3
Correlation of HCV RNA responses and T-cell responses. (A) Mean viral load per dose group. (B) Individual RNA time course in >1 log RNA responders (patients 3013, 4001, 5001). (C and D) Correlation of HCV RNA, liver enzymes, and ELIspot time course in patients 4001 (C) and 3013 (D). (E) Flow cytometry plots and intracellular cytokine stainings for patient 3013.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions

5. Figure 3
Correlation of HCV RNA responses and T-cell responses. (A) Mean viral load per dose group. (B) Individual RNA time course in >1 log RNA responders (patients 3013, 4001, 5001). (C and D) Correlation of HCV RNA, liver enzymes, and ELIspot time course in patients 4001 (C) and 3013 (D). (E) Flow cytometry plots and intracellular cytokine stainings for patient 3013.
Gastroenterology  , e1DOI: ( /j.gastro )
Copyright © 2008 AGA Institute Terms and Conditions